Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide for Osteogenesis Imperfecta
NCT00131469Phase 4Completed
- Sponsor
- Oregon Health & Science University
- Start
- Jun 2005
- Primary completion
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in osteogenesis imperfecta (OI) comparing Teriparatide with Placebo (2 arms). Primary endpoint: Spine Bone Mineral Density at 18 months. Started Jun 2005; status: completed.
02
Drugs
teriparatide
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT00131469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131469.